Vor Biopharma Inc. 8-K
Research Summary
AI-generated summary
Vor Biopharma Inc. Director Resigns; Appoints David Zaccardelli
What Happened Vor Biopharma announced that director Andrew Levin, M.D., Ph.D., resigned from the Board effective July 6, 2026; the company said his resignation was not due to any disagreement with the company. On July 7, 2026 the Board appointed David Zaccardelli, Pharm.D., age 61, as an independent Class II director to fill the vacancy and to serve until the 2029 annual meeting (or until his successor is elected).
Key Details
- Resignation: Andrew Levin resigned effective July 6, 2026; Board thanked him and cited no disagreement with the company.
- Appointment: David Zaccardelli appointed July 7, 2026 as an independent Class II director (term through 2029 annual meeting).
- Background: Zaccardelli founded and manages Bull City Select Investments (since 2016); previously served as CEO and director of Verona Pharma plc (2020–2025, acquired by Merck in Oct 2025), CEO and director of Dova Pharmaceuticals (2018–2019, acquired by Sobi), and Interim CEO of Cempra (2016–2017). He holds a Pharm.D. from the University of Michigan.
- Compensation: Will receive standard non‑employee director cash and equity: $40,000 annual cash retainer (paid quarterly, pro‑rated) and an initial stock option grant equal to the lesser of 68,000 shares or $700,000 grant‑date fair value; eligible for annual option grants of the lesser of 34,000 shares or $350,000 fair‑value at each annual meeting. He will sign the company’s standard indemnification agreement.
- No related‑party transactions or special arrangements were reported in connection with his appointment.
Why It Matters This filing signals a routine board-level change: an experienced biopharma executive with a track record of leading public companies through development and M&A has joined Vor’s board. For investors, the appointment may matter for corporate governance and strategic oversight given Zaccardelli’s CEO experience and prior involvement in companies later acquired. Compensation is typical for non‑employee directors and includes equity that aligns his interests with shareholders.
Loading document...